Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

References

• CheungCMWongTYIs age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatmentJ Intern Med2014276214015324581182
   PubMed Web of Science ®Google Scholar
• EmersonMVLauerAKCurrent and emerging therapies for the treatment of age-related macular degenerationClin Ophthalmol20082237738819668729
   PubMedGoogle Scholar
• RégnierSMalcolmWAllenFWrightJBezlyakVEfficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysisPLoS One201497e10230925029255
   PubMed Web of Science ®Google Scholar
• BrownDMWykoffCCWongTPRanibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trialRetina20143491728173524914476
   PubMed Web of Science ®Google Scholar
• CouturierABousquetEZhaoMAnti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammationMol Vis20142090892024966662
   PubMed Web of Science ®Google Scholar
• CiullaTARosenfeldPJAnti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degenerationCurr Opin Ophthalmol200920316617419381089
   PubMed Web of Science ®Google Scholar
• AcharyaNRSittivarakulWQianYHongKCLeeSMBilateral effect of unilateral ranibizumab in patients with uveitis-related macular edemaRetina20113191871187621716165
   PubMed Web of Science ®Google Scholar
• WuZSaddaSREffects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case reportAnn Acad Med Singapore200837759159318695773
   PubMed Web of Science ®Google Scholar
• LimLSCheungCMMitchellPWongTYEmerging evidence concerning systemic safety of anti-VEGF agents – should ophthalmologists be concerned?Am J Ophthalmol2011152332933121855670
   PubMed Web of Science ®Google Scholar
• HwangDJKimYWWooSJParkKHComparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumabJ Korean Med Sci201227121580158523255862
   PubMed Web of Science ®Google Scholar
• WongTYAge-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapiesAm J Ophthalmol2009148332732919703607
   PubMed Web of Science ®Google Scholar
• CampbellRJBellCMPatersonJMStroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysisOphthalmology201211981604160822717458
   PubMed Web of Science ®Google Scholar
• NassarKGrisantiSElfarELükeJLükeMGrisantiSSerum cytokines as biomarkers for age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2015253569970425056526
   PubMed Web of Science ®Google Scholar
• NitaMMichalska-MałeckaKMazurekUInfluence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degenerationMed Sci Monit20142087588324866589
   PubMed Web of Science ®Google Scholar
• FalkMKSinghAFaberCNissenMHHviidTSørensenTLBlood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case-control studyBMC Ophthalmol2014142224575855
   PubMed Web of Science ®Google Scholar
• OrchelJWitekLKimsaMExpression patterns of kinin-dependent genes in endometrial cancerInt J Gynecol Cancer201222693794422706224
   PubMed Web of Science ®Google Scholar
• AveryRLWhat is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?Br J Ophthalmol201498Suppl 1i7i1024326326
   PubMed Web of Science ®Google Scholar
• ChavanRPanneerselvamSAdhanaPNarendranNYangYBilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degenerationClin Ophthalmol2014871772324748766
   PubMedGoogle Scholar
• CananHSızmazSAltan-YaycıoğluRSarıtürkCYılmazGVisual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosisClin Interv Aging2014914114524453484
   PubMed Web of Science ®Google Scholar
• MoisseievEKatzGMoisseievJSwitching treatment for neovascular age-related macular degeneration from bevacizumab to ranibizumab: who is likely to benefit from the switch?Retina20153571323133026102434
   PubMed Web of Science ®Google Scholar
• CATT Research Group; MartinDFMaguireMGRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)201024111708171520885427
   PubMed Web of Science ®Google Scholar
• KrebsISchmettererLBoltzAA randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBr J Ophthalmol201397326627123292928
   PubMed Web of Science ®Google Scholar
• RouvasALiarakosVSTheodossiadisPThe effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degenerationOphthalmologica2009223638338919602910
   PubMed Web of Science ®Google Scholar
• LükeJNassarKGrisantiSLükeMRegression of rubeosis in the fellow eye after intravitreal ranibizumab injectionGraefes Arch Clin Exp Ophthalmol2013251137137323132337
   PubMed Web of Science ®Google Scholar
• RotsosTSymeonidisCTriantafillopoulouIKanellopoulosSKourisASignificant reduction of diabetic macular edema following intravitreal ranibizumab injection in the fellow eyeInt Ophthalmol20143461271127425192913
   PubMed Web of Science ®Google Scholar
• PescosolidoNFazioSRuscianoDTherapeutic improvement in the contralateral eye after ranibizumab intravitreal treatment in a patient affected by bilateral subfoveal choroidal neovascularizationJSM Biotechnol Bioeng2014221038
   Google Scholar
• Al-DhibiHKhanAOBilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edemaJ AAPOS200913440040219482498
   PubMed Web of Science ®Google Scholar
• SharmaAShethJMadhusudanRJSundaramoorthySKEffect of intravitreal dexamethasone implant on the contralateral eye: a case reportRetin Cases Brief Rep20137321721925391109
   PubMedGoogle Scholar
• HosseiniHLotfiMEsfahaniMHEffect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degenerationRetina201232596797122146127
   PubMed Web of Science ®Google Scholar
• AveryRLCastellarinAASteinleNCSystemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMDBr J Ophthalmol201498121636164125001321
   PubMed Web of Science ®Google Scholar
• MoisseievEWaisbourdMBen-ArtsiEPharmacokinetics of bevacizumab after topical and intravitreal administration in human eyesGraefes Arch Clin Exp Ophthalmol2014252233133724170282
   PubMed Web of Science ®Google Scholar
• XuLLuTTuomiLPharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approachInvest Ophthalmol Vis Sci20135431616162423361508
   PubMed Web of Science ®Google Scholar
• BakriSJSnyderMRReidJMPulidoJSEzzatMKSinghRJPharmacokinetics of intravitreal bevacizumab (Avastin)Ophthalmology2007114585585917467524
   PubMed Web of Science ®Google Scholar
• GaudreaultJFeiDRusitJSubocPShiuVPreclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administrationInvest Ophthalmol Vis Sci200546272673315671306
   PubMed Web of Science ®Google Scholar
• ChristoforidisJRickettsRPrattCThe effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit modelClin Ophthalmol20126616922275809
   PubMedGoogle Scholar
• ChristoforidisJBWangJJiangAThe effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healingClin Ophthalmol2013718519123378736
   PubMedGoogle Scholar
• GolanSEntin-MeerMSemoYGene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatmentBMC Res Notes2014761725201034
   PubMedGoogle Scholar
• MoFMProiaADJohnsonWHCyrDLashkariKInterferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degenerationInvest Ophthalmol Vis Sci20105184226423620220052
   PubMed Web of Science ®Google Scholar
• DabirSSDasDNallathambiJMangaleshSYadavNKSchoutenJSDifferential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatmentIndian J Ophthalmol2014621667324492504
   PubMed Web of Science ®Google Scholar
• WangXSawadaTSawadaOSaishinYLiuPOhjiMSerum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degenerationAm J Ophthalmol2014158473874424973606
   PubMed Web of Science ®Google Scholar
• CarneiroAMCostaRFalcãoMSVascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumabActa Ophthalmol2012901e25e3021958440
   PubMed Web of Science ®Google Scholar
• ZehetnerCKralingerMTModiYSSystemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trialActa Ophthalmol2015932e154e15925488124
   PubMed Web of Science ®Google Scholar
• WangDChoiKSLeeSJSerum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumabKorean J Ophthalmol2014281323824505199
   PubMedGoogle Scholar
• SizmazSKucukerdonmezCKalAPinarciEYCananHYilmazGRetinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumabEur J Ophthalmol201424690491024803153
   PubMed Web of Science ®Google Scholar